What Is Hormone Replacement Therapy (HRT)?

Introduction

Hormone replacement therapy (HRT) is one of the most widely discussed and misunderstood treatments in modern medicine. This is perhaps because of its efficacy in relieving menopause symptoms or its widespread action on multiple organs, including the brain, bones, heart, and digestive and reproductive systems. Despite this, it remains poorly understood, partly due to inconsistent research findings, the way they are reported, and oversimplified media coverage.

There’s some confusion surrounding the 2002 Women’s Health Initiative trial (WHI), which reported an association between conventional HRT regimens and a higher risk of breast cancer and heart disease (1). After these results were widely scrutinized, it was found that the study didn’t adjust for some important factors like patient age, individual health risks, and timing around menopause. These factors can significantly influence risk and may affect how results are interpreted. After adjusting for these factors in later analyses, several of the reported associations were no longer statistically significant (2). Although the findings were later re-evaluated, the study still shapes public perception and prescribing habits in some cases.

HRT isn’t a one-size-fits-all therapy, and the outcomes and risks vary widely and are based on multiple factors like patient age and risk profile, symptoms, health status, timing around menopause, formulation, and dosage. There has been a marked transition from conventional approaches toward a more individualized strategy based on these personal factors.

At the same time, HRT has become part of broader healthcare and policy discussions, particularly in areas such as menopause care and gender-affirming treatment. These debates can further complicate public understanding of HRT and influence access to care.

This article explains what HRT is, who it’s for, how it works in the body, the potential benefits and risks, and how policy can shape access to treatment.

What Is Hormone Replacement Therapy (HRT)?

What HRT Means Medically

Hormone replacement therapy (HRT) refers to the use of prescribed hormones to replace or supplement endogenous hormones in the body that have declined or are insufficient. These hormones most commonly include estrogen, progesterone (or synthetic forms known as progestins), and in some cases testosterone, either alone or in combination depending on the clinical situation (3).

Although HRT is most commonly associated with treatment of symptoms associated with menopause, it is also used in several clinical contexts beyond that, including premature or early menopause, certain forms of testosterone deficiency, and gender-affirming hormone therapy. In each of these situations, the goal is to relieve symptoms or restore hormone balance to support normal physiological function.

Hormone Overview

Estrogen Therapy

• Primary hormone used in most HRT regimens
• Common forms include conjugated estrogens (CE), micronized 17β-estradiol (which is structurally identical to the estradiol produced by the ovaries), and ethinyl estradiol, which is more commonly used in hormonal contraceptives rather than menopausal HRT. Conjugated equine estrogens (CEE), used in the Women’s Health Initiative trials, are one example of conjugated estrogen formulations (4)
• Main use: replacement for estrogen deficiency, and relief of symptoms of menopause and perimenopause

Progestogens (general category including progesterone and synthetic progestins)

• Typically prescribed in combination with estrogen for individuals who have a uterus for endometrial protection
• Purpose: progestogen therapy prevents endometrial overgrowth and protects against endometrial (uterine) cancer (5). When estrogen is used alone, it can cause endometrial hyperplasia (thickening of the uterus lining), which may increase the risk of endometrial cancer
• Forms include micronized progesterone (which is identical in structure to the progesterone produced by the corpus luteum in the ovaries) or synthetic progestins, which mimic progesterone’s effects on the endometrium (4).

Testosterone Therapy

• Prescribed for clinically diagnosed testosterone deficiency or symptomatic hypogonadism (6)
• Used in gender-affirming hormone therapy and, less commonly, off-label for persistently low libido (clinically referred to as hypoactive sexual desire disorder) in postmenopausal individuals (7,3).
• Needs specialist assessment and monitoring

Combination regimens

• The hormones mentioned above may be used alone or in combination, depending on the patient’s clinical situation and therapeutic goals
• Combinations may include estrogen + progestin (the classic HRT therapy) or testosterone added to a regimen in cases of confirmed deficiency or as part of gender-affirming hormone therapy

Why Do People Use HRT?

HRT can be prescribed across several clinical contexts. While the term “HRT” is an umbrella term for treatments replacing hormones, including estrogen, progestins, or testosterone, clinicians tend to distinguish between the different forms of HRT by the underlying condition.

The most common categories of HRT include menopausal hormone therapy (this is often just called “HRT”), testosterone replacement therapy, and gender-affirming hormone therapy. Other cases for HRT are also explained below.

1. Menopausal Hormone Therapy (MHT)

Menopausal hormone therapy (MHT) is most commonly used to manage moderate to severe symptoms associated with menopause and perimenopause (3). Menopause is the point at which menstrual periods stop; this is defined as 12 consecutive months without a period, and on average, it happens around 51 years of age. Perimenopause is the transitional stage leading up to menopause, where hormone levels fluctuate and symptoms can begin (5). These symptoms can vary widely in severity and can affect multiple organ systems.

MHT may be used to treat the following:

• Vasomotor symptoms (VMS): Hot flashes and night sweats, collectively known as vasomotor symptoms, are the most disruptive and common symptoms of menopause, affecting up to 80% of menopausal individuals (8). MHT is the most effective treatment for VMS (4).
  
• Genitourinary syndrome of menopause (GSM): A condition causing vaginal dryness and irritation, discomfort during sex, and urinary symptoms due to declining estrogen levels. GSM affects between 27-84% of postmenopausal individuals and can have a significant impairment in quality of life and sexual health (9) In people whose symptoms are limited to the genitourinary tract, FDA guidance recommends using low-dose topical vaginal estrogen instead of systemic hormone therapy (9).
  
• Osteoporosis and fracture risk: Estrogen plays a key role in maintaining bone density. After menopause, when estrogen levels decline, the accelerated bone loss may increase the risk of osteoporosis and fractures, which are more common in older postmenopausal individuals (10). MHT may help prevent bone loss.
  
• Sleep disturbances and mood changes: Sleep disturbances are common during the menopausal transition. Vasomotor symptoms can disrupt sleep, and poor sleep quality has been linked to mood fluctuations, memory problems, and increased cardiometabolic risk. Hormone therapy may help to improve sleep quality, particularly when the sleep disruption is related to VMS (4).

According to guidance from the Menopause Society, MHT is FDA-approved for several indications. These include relief of moderate to severe vasomotor symptoms, prevention of osteoporosis in postmenopausal individuals, treatment of low levels of estrogen resulting from conditions such as hypogonadism, bilateral oophorectomy (removal of the ovaries), or primary ovarian insufficiency, which can cause premature menopause, and treatment of moderate to severe vulvovaginal symptoms (4).

2. Testosterone Replacement Therapy (TRT)

Testosterone replacement therapy (TRT) is prescribed for individuals with symptomatic and clinically confirmed testosterone deficiency, commonly referred to as hypogonadism. Testosterone levels decline naturally with age, but not all testosterone decreases require medical treatment. Clinical practice guidelines from the Endocrine Society recommend TRT only when there are consistently low testosterone levels together with relevant symptoms (6).

Common symptoms and clinical features associated with testosterone deficiency according to the Endocrine Society may include:

Suggestive Symptoms

• Reduced libido
• Erectile dysfunction
• Breast discomfort or gynecomastia
• Low bone density or height-loss

General Symptoms

• Persistent fatigue
• Loss of muscle mass and strength
• Mood changes
• Poor concentration or memory
• Sleep disturbances
• Mild unexplained anemia
• Increased BMI

Note: The guideline also lists “specific” symptoms (very small testes, delayed sexual development, loss of axillary/pubic hair), which mostly indicate congenital or severe hypogonadism.

TRT should be prescribed only after confirming consistently low testosterone levels with associated symptoms, as use in age-related testosterone decline without clear symptoms may provide limited benefit. Long-term risks, including cardiovascular effects, increases in hematocrit (red blood cell levels), and prostate health, remain incompletely understood, and patients receiving therapy should be monitored regularly.

Testosterone Therapy in Menopause

Testosterone may be used off-label for hypoactive sexual desire disorder (HSDD) – persistently low libido causing distress – after other causes have been excluded and conventional hormone therapy has been tried. Randomized clinical trials show that transdermal testosterone patches or creams can improve symptoms, but long-term safety data and risks aren’t yet fully established (3).

3. Gender-Affirming Hormone Therapy (GAHT)

Gender-affirming hormone therapy (GAHT) may be used to help align an individual’s physical characteristics with their gender identity. Treatment is highly individualized and focuses on using hormone regimens that promote the development of secondary sex characteristics consistent with the person’s affirmed gender (11). The main treatment categories are transfeminine and transmasculine hormone therapy, each with distinct hormone regimens and risk profiles.

Fertility and parenting desires should be discussed before initiating hormone therapy, as treatment may affect reproductive function.

Transfeminine hormone therapy

For transfeminine individuals, treatment usually includes estrogen and anti-androgens to suppress endogenous testosterone. Effects may include decreased erectile function and testicular size, breast growth, and increased body fat percentage. Possible risks may include venous thromboembolism (blood clots), hypertriglyceridemia (elevated lipid level), gallstones, and elevated liver enzymes. Individuals should be counselled to reduce heart disease risk factors like smoking (12).

Transmasculine hormone therapy

For transmasculine individuals, testosterone therapy promotes changes including facial and body hair growth, deepening of the voice, and increased muscle mass. Additional effects may include fat redistribution, cessation of menstruation, increased libido, and possible hairline recession. Testosterone therapy may reduce fertility, but it’s possible that ovulation can still occur, so it’s important to discuss contraception and reproductive planning when relevant for the individual. Contraindications include pregnancy, coronary heart disease, and polycythemia (high levels of red blood cells) (12).

Although hormone therapy is recognized as medically necessary for many transgender patients with gender dysphoria by major medical associations, including the American College of Obstetricians and Gynecologists (ACOG), the World Professional Association for Transgender Health (WPATH), and the Endocrine Society, not all transgender individuals experience gender dysphoria or want hormone therapy (12,7,13).

4. Additional Use Cases for HRT

Beyond the main categories above, HRT may be used in several other clinical scenarios:

Premature Ovarian Insufficiency (POI): Early loss of ovarian function in individuals younger than 40 results in premature menopause. HRT is typically offered until the average age of natural menopause to alleviate symptoms and reduce long-term risks of having low estrogen, including cardiovascular disease and osteoporosis. POI can also result from medical therapies like chemotherapy or radiation to the pelvis (3).

Surgical Menopause: Individuals who undergo surgical removal of both ovaries may experience an abrupt estrogen deficiency. HRT may be offered until the age of natural menopause to manage symptoms and protect long-term health (3).

How HRT Works in the Body

HRT works by replacing missing or depleted hormones. These hormones act as chemical messengers throughout your body, binding to estrogen, progesterone, or androgen receptors in target tissues to produce their physiological effects.

Menopausal Hormone Therapy (MHT)

As menopause approaches, the ovaries produce less estrogen and progesterone. Hormone therapy can replace these hormones to relieve symptoms.

Delivery Methods

• Systemic estrogen therapy: Pills, transdermal patches, sprays and gels deliver estrogen into the bloodstream, acting directly on multiple tissues (5)
  • Pros: Very effective for vasomotor symptoms
  • Cons: Oral estrogen is metabolised in the liver before entering systemic circulation, which may influence clotting factors and lipid levels
• Local estrogen therapy: vaginal ring, tablet or cream, which release small amounts of estrogen directly into the vaginal tissue (5)
  • Pros: targeted relief for genitourinary symptoms
  • Cons: limited effect on systemic symptoms
• Progestogen options
  • Added for individuals with a uterus
  • Available as oral pills, vaginal tablets or gels, or combination patches with estrogen
• Dosing guidance: The therapeutic goal is to use the lowest effective dose of systemic treatment for adequate symptom relief

Testosterone Replacement Therapy (TRT)

TRT restores androgen levels in people with symptomatic and clinically confirmed deficiency. Testosterone acts via androgen receptors across multiple organ systems and tissues in the body including muscle, bone, and brain, as well as metabolic and reproductive systems.

Delivery Methods (14)

• Transdermal gels or solutions: Applied daily to the skin, typically on the shoulders or upper arms
  • Pros: Convenient, avoids injections, maintains relatively stable testosterone levels
  • Cons: Risk of transfer through skin contact; absorption can vary depending on site of application
• Intramuscular injections: usually administered weekly or at regular intervals
  • Pros: Widely used and effective for restoring testosterone levels
  • Cons: Hormone levels can fluctuate between doses
• Subcutaneous pellets: implanted under the skin every 3-6 months
  • Pros: Long-acting hormone release
  • Cons: Minor surgical procedure and repeated insertions
• Intranasal testosterone gel: Applied multiple times daily
  • Pros: Avoids risk of skin transfer
  • Cons: Inconvenience of frequent dosing
• Oral testosterone undecanoate: Recently approved formulation which is absorbed through the intestinal lymphatics so it bypasses liver metabolism
  • Pros: Avoids hepatic toxicity seen with older oral testosterone pills
  • Cons: Costly and need to take twice a day

These mechanisms also apply to other indications for hormone therapy, including gender-affirming hormone therapy, which uses similar hormone classes and delivery methods

Benefits of HRT

The benefits of HRT depend on the underlying condition being treated.

For Menopause:

• Reduction in vasomotor symptoms: Approximately 75% reduction in hot flashes (15). Systemic estrogen therapy is the most effective treatment for vasomotor symptoms like hot flashes and night sweats.
• Bone density preservation: Estrogen therapy helps prevent accelerated bone loss after menopause as well as reduce the risk of fractures
• Genitourinary health: Local vaginal estrogen therapy can relieve vaginal dryness and irritation
• Colon cancer risk reduction: HRT may also reduce the risk of colorectal cancer (16,17)

For Testosterone Deficiency (14):

• Libido and sexual function: Statistically significant improvements in sexual desire and erectile function in hypogonadal men
• Muscle and bone: Increases lean body mass and bone mineral density
• Mood and energy: Improvements in anemia have been shown in clinical trials, and effects on energy, fatigue, and mood are possible, but studies are inconclusive
  

For Gender-Affirming Care (13,18):

• Secondary sex characteristic alignment: Hormone therapy aligns physical traits with affirmed gender
• Improved mental health outcomes
• Reduced gender dysphoria
  

Risks and Side Effects of HRT

Like most medical treatments, HRT carries some known risks, which vary depending on the type and dosage of hormone, the route of administration, and individual patient factors. These risks need to be weighed against the potential benefits and discussed with a healthcare provider as part of an individualized treatment plan.

Menopausal HRT Risks (4,5):

• Endometrial cancer: Estrogen-only therapy in people with a uterus can cause the lining of the uterus to thicken, increasing endometrial cancer risk. Taking progestin alongside estrogen protects the endometrium and lowers this risk.
• Breast cancer: Combined estrogen-progestin therapy carries a small increased risk; estrogen-only therapy may have a lower risk. Women with a history of hormone-sensitive breast cancer are usually advised to try non-hormonal therapies.
• Cardiovascular disease:
  • Combined therapy may slightly increase the risk of heart attack in older women.
  • Starting therapy within 10 years of menopause and under age 60 may be cardioprotective, especially with estrogen-only therapy.
  • Combined therapy should not be used to prevent heart disease.
• Stroke and blood clots (venous thromboembolism): Risk increases with age, using oral estrogen, and comorbidities like heart disease, kidney disease, or obesity. Non-oral routes such as patches, sprays, or rings may carry less risk.
• Gallbladder disease: Slightly higher risk, especially with oral estrogen therapy.
• Fertility impact: Hormone therapy can affect reproductive function.
• Common side effects: Nausea, bloating, fluid retention, weight gain, mood changes (progestogen-related), breakthrough bleeding, headaches, and breast tenderness.
  

Factors Influencing Risk (Menopausal HRT) (4):

• Age at initiation and years since menopause
  • Guidance from the Menopause Society advises that for people under 60 years of age or within 10 years of menopause, the benefits outweigh risks for symptom relief and bone protection.
  • For women over 60 years of age or more than 10 years post-menopause, absolute risks increase for heart disease, stroke, blood clots, and dementia, and the benefit-risk ratio is less favorable. 
• Personal health and family history
• Hormone type, dose, combination, and route of administration
• Duration of therapy

Testosterone Replacement Therapy (TRT) Risks (14):

• Fertility impact: TRT significantly reduces sperm production and may affect fertility.
• Cardiovascular risk and blood clots: There is currently conflicting evidence as to whether there’s any increased risk of heart attack or blood clots, but it’s currently recommended that testosterone therapy should be deferred for at least 3 months after a major cardiovascular event.
• Prostate effects: TRT can stimulate benign prostatic growth, and prostate monitoring is recommended, but there is no conclusive evidence that TRT increases the risk of developing new prostate cancer.
• Liver toxicity: Certain oral formulations are associated with liver toxicity, but newer oral testosterone decanoate is generally safer.
• Other adverse effects: Skin reactions to gels/patches.
• Contraindications: Include a history of breast or prostate cancer or heart failure.
• Monitoring considerations: Regular assessment of testosterone levels, hemoglobin/ hematocrit (to assess red blood cell levels), and prostate monitoring for those who choose it (6).

Gender-Affirming Hormone Therapy (GAHT) Risks (7,13):

• The risks of GAHT are mostly aligned with those of estrogen and testosterone therapy described above and depend on the hormone type, dose, and route of administration.
• Hormone levels above physiologic ranges may increase the risk of adverse events, highlighting the need for individualized dosing, clinical assessments, and monitoring of hormone levels.
• Cardiovascular risk factors like blood pressure and lipid levels should be assessed.
• Routine cancer screening should follow guidelines based on the organs present.
• The risk of infertility should be discussed before initiating therapy.

What HRT Does NOT Guarantee

Understanding how HRT works is important, but so is knowing its limits, especially in the context of longevity and anti-aging medicine. 

• It is not an anti-aging cure. While HRT may address some skin changes like hydration and elasticity, the evidence is mixed, and it cannot reverse all aspects of aging (19).
• It does not reverse all metabolic changes associated with menopause, but it may help attenuate certain metabolic changes like visceral fat accumulation and insulin resistance, but results across studies are inconsistent (20).
• It does not eliminate cardiovascular risk. While the timing of initiating HRT around menopause matters as to how it influences cardiovascular health, HRT is not a treatment for heart disease prevention.
• It is not risk-free. Regular monitoring is needed, and the risks and benefits should be carefully balanced.
  

Bioidentical vs FDA-Approved Hormones

The term bioidentical means the hormone is structurally identical to the hormones the body naturally makes. Not all bioidenticals are the same; some are FDA-approved medications that have been tested for safety, effectiveness and quality. These include plant-derived hormones like micronized progesterone, estradiol, and DHEA, and they’re prescribed regularly as part of HRT.

There’s also a parallel market of compounded bioidentical hormones, which are prepared by compounding pharmacies based on a clinician’s prescription. These products are not regulated by the FDA in the same way as approved medications, and their formulations are customized for individual patients.

Compounded hormones are sometimes marketed as being more “natural” or safer because they’re plant-derived or tailored to the individual. However, current scientific evidence does not show that compounded bioidentical hormones are safer or more effective than FDA-approved HRT (5).

Compounded medications may still be appropriate in certain circumstances. For example, they may be used if a patient needs a specific dose or formulation that is not commercially available, or if they have an allergy or intolerance to an ingredient in an FDA-approved product.

The American College of Obstetricians and Gynecologists (ACOG) advises that FDA-approved HRT are used as the first-line option for managing menopausal symptoms (21).

Comparison Table: Types of HRT

The table below summarizes the three main categories of HRT, including their primary use, delivery methods, and typical prescribing providers.

Type of HRT	Primary Use	Common Hormones	Delivery Methods	Typical Provider	Insurance Coverage
Menopausal HRT	Menopause	Estrogen ± Progestin	Oral, patch, spray, gel, vaginal ring/cream	OB-GYN, PCP	Often covered, varies by plan
Testosterone Therapy	Hypogonadism	Testosterone	Injection, gel, pellet, oral	Endocrinologist, Urologist	Varies by plan
Gender-Affirming HRT	Gender transition	Estrogen or Testosterone	Injection, patch, gel, oral	Endocrinologist, OB-GYN, PCP, or other trained clinicians	Varies by state and plan

Table 1. Common hormones, delivery methods, and prescribing providers may vary depending on the individual patient and clinical context. Insurance coverage also differs by insurer, plan, and state policy. Adapted from ACOG, the Endocrine Society, Kaiser Family Foundation, and StatPearls. (5,6,14,22)

Policy & Access Landscape

In the United States, insurance coverage for HRT varies by state and plan. In some states, private insurance plans are required to cover certain hormone therapies, while in other states insurers have more flexibility in deciding coverage. This results in variation between states and insurance plans (23). People seeking hormone therapy may experience differences in coverage, authorization requirements, and out-of-pocket costs depending on where they live and which insurance plan they have. Requirements and coverage vary by state; individuals should check with their insurance provider and state regulations for current policies.

Medicaid coverage can also differ across states. While the federal government sets mandatory benefits and rules to ensure fairness, states have the flexibility to decide which additional services to cover. This may create variation in access to HRT for Medicaid members depending on where they live. Federal policy proposals may further influence coverage. Recent proposals from the Centers for Medicare & Medicaid Services could limit the use of Medicaid for gender-affirming care in minors if implemented, affecting access in a growing number of US states (24,25). The Kaiser Family Foundation’s Gender-Affirming Care Policy Tracker provides an up-to-date overview of current state-level policies (26). According to the tracker, 27 states have enacted laws or policies restricting youth access to gender-affirming care.

Access to HRT consultations has increased with telehealth service expansion, allowing online consultations and prescriptions for HRT.

At the federal level, hormone medications are regulated by the FDA, which ensures that hormone products meet standards for safety and effectiveness. This regulation also affects access. The FDA recently removed the black box warning on estrogen therapy regarding risks of heart disease, breast cancer, and dementia, reflecting updated evidence on safety (27).

How to Know If You’re a Candidate

HRT is not appropriate for everyone, and the decision to start treatment should only be made after a thorough clinical assessment has been done, in collaboration with your healthcare provider.

Symptom Review

• Track your symptoms like hot flashes, night sweats, mood changes, sleep disturbances, vaginal dryness, or libido changes.
• Note your symptom severity, frequency, and how it affects your daily life.
• Your clinician will review your symptoms along with your medical history to determine if HRT may be helpful for you.
  

Lab Testing (3)

Before starting HRT, you may need to have some blood tests to check hormone levels and overall health to help guide safe treatment. This may include the following:

• Hormone levels
• Blood tests for baseline organ function, including kidney, liver, and lipid profile

A good medical response to treatment is usually judged by the improvement of symptoms rather than lab tests.

Risk Screening and Contraindications  (5,3)

• Contraindications (do not start HRT if present):
  • Current or recent pregnancy
  • A personal history of hormone-sensitive cancers, including breast, endometrial, or ovarian cancer
  • Active or recent venous thromboembolism (blood clots)
  • Cardiovascular disease or history of stroke or heart attack
  • Uncontrolled liver disease
  • Unexplained vaginal bleeding

• Other risk factors to discuss:
  • Cardiovascular disease risk
  • Family history of breast or ovarian cancer
  • Bone density concerns (HRT may help maintain bone mass)
  • Any chronic conditions
    

Shared Decision-Making (5)

Decisions should be made together with your clinician, weighing potential risks with benefits and personal preference. Discuss goals of treatment and reassess every year and decide whether to continue HRT.

Questions to Ask Your Clinician

1. Based on my age, symptoms, and medical history, am I a good candidate for HRT?
2. What type and form of HRT would be safest for me?
3. How will we monitor my response to treatment?
4. How long would you recommend I take HRT?
5. What side effects can I expect?

Research Toolkit

• ACOG guidelines – Evidence-based guidance on HRT for menopause, including frequently-asked questions
  
• Endocrine Society clinical practice guidelines – Evidence-based recommendations for initiation, monitoring, and maintenance of hormone therapy in adults and adolescents with gender dysphoria
  
• North American Menopause Society (NAMS) – Comprehensive resource on hormone therapy for menopause, including indications, risks, and benefits based on the latest evidence
  
• WPATH Standards of Care 8 – Clinical guidance on gender-affirming care for transgender and gender-diverse individuals
  
• FDA hormone therapy safety – Official FDA resource explaining menopause, hormone therapy and non-hormone treatment options, and safety considerations
  
• CDC menopause – A CDC health topic page offering public health information on menopause

FAQs

1. Is HRT safe after age 60?

It depends on individual health factors and timing. Current evidence suggests that starting HRT after age 60 (or more than 10 years after menopause) may be associated with an increased risk of heart disease, stroke, blood clots, and dementia, so the balance of benefits and risks may be less favorable. That being said, HRT can still be appropriate for some women over 60 under careful clinical assessment.

2. How long can I stay on HRT?

There’s no universal time limit. Duration should be based on ongoing symptom benefit and individual risk profile, as long as there are annual risk assessments.

3. Are compounded bioidentical hormones safer than FDA-approved HRT?

Compounded hormones are customized by pharmacies and are not regulated by the FDA like approved products. There is no strong evidence that they are safer or more effective. FDA-approved bioidentical hormones exist and are recommended as the first-line choice. Compounded options may be appropriate in specific cases, such as when a patient needs a specific dose or formulation or has an allergy to an ingredient in an approved product.

4. Does HRT cause weight gain?

Weight gain is a common concern, but evidence suggests that HRT does not directly cause significant weight gain (though some people may notice temporary bloating or fluid retention). During menopause, body fat may shift towards a more central distribution (like the abdomen), which HRT may actually help reduce in some individuals.

Expert Perspective

As a medical doctor and current medical writer with a focus on hormonal and metabolic health, much of my work involves reviewing the complex and sometimes contradictory evidence base around hormone therapies, and few areas illustrate this better than HRT.

The 2002 Women’s Health Initiative findings had an effect on prescribing culture, and the sharp decline in HRT use that followed had real consequences for people who may have genuinely benefited from treatment. In some ways, though, the controversy wasn’t without value. It allowed an honest conversation, one that moved away from blanket prescribing toward genuinely individualized care. We now understand that risk depends heavily on factors like age at initiation, timing of treatment relative to menopause, the type and route of hormones used, and each patient’s personal health history. It’s a reflection of how complex hormonal health is.

What I find most important in clinical discussions around HRT is the shift toward evidence-based, shared decision-making. Rather than asking, “Is HRT safe?” We should ask, “Is HRT appropriate for this person, at this stage, with this health profile?” Patients deserve to have that question answered properly and truthfully. 

Conclusion

HRT encompasses a range of hormone-based therapies across multiple clinical contexts, from menopause symptom management and testosterone deficiency to gender-affirming care and premature ovarian insufficiency. Each has its own evidence base, risks, and considerations.

Evidence has evolved considerably over time, clarifying both advantages and limitations of HRT, and current guidelines support HRT use in certain individuals. It’s not suitable for everyone, and it’s important that treatment is individualized for each person with risks and benefits weighed against their health profile. Policy and access remain barriers for some patients, especially with gender-affirming care and the variability of insurance coverage across states.

Ultimately, informed decision-making matters. Patients who are well-informed about their options are best placed to make choices that are right for them. 

References

1. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288(3):321–33. Available from: https://jamanetwork.com/journals/jama/fullarticle/195120 
2.  Khalifey HT, Mahereen R, Adwan R, Chahine R, Kaidali M, Mirza SF, et al. The impact of hormone replacement therapy on cardiovascular health in postmenopausal women: a narrative review. Front Reprod Health. 2026;8:1745210. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12872825/ 
3. Harper-Harrison G, Carlson K, Shanahan M. Hormone Replacement Therapy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [updated 2024 Oct 6]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493191/
4. The 2022 hormone therapy position statement of The Menopause Society. Menopause. 2022;29(7):767–94. Available from: https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
5. American College of Obstetricians and Gynecologists. Hormone therapy for menopause [Internet]. Washington, DC: ACOG; 2024. Available from: https://www.acog.org/womens-health/faqs/hormone-therapy-for-menopause
6. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–44. Available from: https://academic.oup.com/jcem/article/103/5/1715/4939465
7. Coleman E, Radix AE, Bouman WP, Brown GR, de Vries ALC, Deutsch MB, et al. Standards of care for the health of transgender and gender-diverse people, version 8. Int J Transgend Health. 2022;23(Suppl 1):S1–259. Available from: https://www.tandfonline.com/doi/full/10.1080/26895269.2022.2100644 
8. The 2023 nonhormone therapy position statement of the North American Menopause Society. Menopause. 2023;30(6):573-590. Available from: https://menopause.org/wp-content/uploads/professional/2023-nonhormone-therapy-position-statement.pdf
9. The 2020 genitourinary syndrome of menopause position statement of the North American Menopause Society. Menopause. 2020;27(9):976-992. Available from: https://menopause.org/wp-content/uploads/professional/The_2020_genitourinary_syndrome_of_menopause.5.pdf
10. Management of osteoporosis in postmenopausal women: the 2021 position statement of the North American Menopause Society. Menopause. 2021;28(9):973-997. Available from: https://menopause.org/wp-content/uploads/professional/2021-osteoporosis-position-statement_577e5813-cdfa-4d5f-a7f2-3c3f3ec0e4c9.pdf
11. Miroshnychenko A, Ibrahim S, Roldan Y, Kulatunga-Moruzi C, Montante S, Couban R, et al. Gender-affirming hormone therapy for individuals with gender dysphoria aged <26 years: a systematic review and meta-analysis. Arch Dis Child. 2025 May 16; 16;110(6):437-445. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12171493/
12. American College of Obstetricians and Gynecologists. Health care for transgender and gender-diverse individuals. Committee Opinion No. 823. [Internet] Washington DC: ACOG; 2021;137(3):e75–88. Available from: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2021/03/health-care-for-transgender-and-gender-diverse-individuals
13. Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–903. Available from: https://academic.oup.com/jcem/article/102/11/3869/4157558 
14. Sizar O, Leslie SW, Schwartz J. Male Hypogonadism. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from:  https://www.ncbi.nlm.nih.gov/books/NBK532933/
15. Lugo T, Tetrokalashvili M. Hot Flashes. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539827/ 
16. Liu Q, Simin J, Debelius J, Fall K, Sadr-Azodi O, Engstrand L, et al. Menopausal hormone therapies and risk of colorectal cancer: a Swedish matched-cohort study. Aliment Pharmacol Ther. 2021 Jun;53(11):1216-1225. Available from: https://pubmed.ncbi.nlm.nih.gov/33857339/
17. Labadie JD, Harrison TA, Banbury B, Amtay EL, Bernd S, Brenner H, et al. Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location, JNCI Cancer Spectrum. 2020; 4(5). Available from: https://academic.oup.com/jncics/article/4/5/pkaa042/5840479 
18. Tordoff DM, Wanta JW, Collin A, Stepney C, Inwards-Breland DJ, Ahrens K. Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care. JAMA Netw Open. 2022 Feb 1;5(2):e220978. Erratum in: JAMA Netw Open. 2022 Jul 1;5(7). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8881768/
19. Viscomi B, Muniz M, Sattler S. Managing Menopausal Skin Changes: A Narrative Review of Skin Quality Changes, Their Aesthetic Impact, and the Actual Role of Hormone Replacement Therapy in Improvement. J Cosmet Dermatol. 2025 Sep;24 Suppl 4(Suppl 4):e70393. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12374573/
20. Lovre D, Lindsey SH, Mauvais-Jarvis F. Effect of menopausal hormone therapy on components of the metabolic syndrome. Ther Adv Cardiovasc Dis. 2016 May 27;11(1):33–43. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC5933555/
21. American College of Obstetricians and Gynecologists. Compounded bioidentical menopausal hormone therapy. Clinical Consensus No. 6. [Internet] Washington DC: ACOG; 2023;142(6):1358–66. Available from: https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapy
22. Gomez I, Ranji U, Salganicoff A,Dawson L, Rosenzweig C, Kellenberg R, et al. Update on medicaid coverage of gender-affirming health services [Internet]. Kaiser Family Foundation; San Francisco: KFF; 2022. Available from: https://www.kff.org/womens-health-policy/update-on-medicaid-coverage-of-gender-affirming-health-services/
23. Kaiser Family Foundation. Do marketplace plans cover gender-affirming care? What changes have there been to coverage requirements?  [Internet]. San Francisco: KFF; 2025. Available from: https://www.kff.org/faqs/faqs-health-insurance-marketplace-and-the-aca/marketplace-basics/do-marketplace-plans-cover-gender-affirming-care-what-changes-have-there-been-to-coverage-requirements/
24. Dawson L, Pestaina K, Rae M. New rule proposes changes to ACA coverage of gender-affirming care, potentially increasing costs for consumers. [Internet]. San Francisco: KFF; 2025. Available from: https://www.kff.org/private-insurance/new-rule-proposes-changes-to-aca-coverage-of-gender-affirming-care-potentially-increasing-costs-for-consumers/
25. Dawson L, Hulver S. New Trump administration proposals would further limit gender-affirming care for young people by restricting providers and reducing coverage. [Internet]. San Francisco: KFF; 2025. Available from:  https://www.kff.org/lgbtq/new-trump-administration-proposals-would-further-limit-gender-affirming-care-for-young-people-by-restricting-providers-and-reducing-coverage/ 
26. Kaiser Family Foundation. Policy tracker: youth access to gender-affirming care and state policy restrictions. [Internet]. San Francisco: KFF; 2025. Available from: . https://www.kff.org/lgbtq/gender-affirming-care-policy-tracker/
27. US Food and Drug Administration. HHS advances women’s health, removes misleading FDA warnings on hormone replacement therapy [Internet]. Silver Spring: FDA; 2025. Available from: https://www.fda.gov/news-events/press-announcements/hhs-advances-womens-health-removes-misleading-fda-warnings-hormone-replacement-therapy